Combined with the previous results of HPLC-Q-TOF/MS, bioinformatics and molecular docking, we supposed that WSF treatment could ameliorate hepatic lipid disorder and inflammation injury in NAFLD through regulation of the TLR4/NF-κB/COX-2 signaling pathway. The gene discussed is PTGS2; the disease is metabolic dysfunction-associated steatotic liver disease.